"I find that mind blowing." Related Cosmetic surgeons try to correct 'Ozempic face' for weight-loss drug users FDA issues black box warning for hot flash drug Veozah Study: Non-heterosexual women ...

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...

On February 4, Merck released financial results for Q4 2024, which, as in previous quarters, once again beat analysts' expectations. This was driven by a strong performance by its oncology ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more reasons than one. Along with a key U.S. patent expiring at the end of ...

Product liability refers to cases where defective goods cause harm. People expect the products they buy to work as intended. But when these products are defective, those who use them may be unjustly ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting negotiations next year under the Inflation Reduction Act. In a filing with ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader drug portfolio continues to perform well and is driving a strong earnings ...

American College of Obstetricians and Gynecologists. Hormone therapy for menopause. DailyMed. Label: VEOZAH- fezolinetant tablet, film coated.

Bias and stigma are to blame for the way women’s health research has fallen behind, according to Monica Christmas, M.D., director of UChicago Medicine’s menopause program and the Center for Women's ...

Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public attention lately after HHS Secretary Robert F. Kennedy Jr.'s links to the ...

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid concerns that jurors might be influenced by controversy this month around ...

The U.S. biotech is paying (PDF) China’s CSPC Megalith Biopharmaceutical $15 million upfront for rights to an antibody-drug conjugate (ADC), securing itself a shot at challenging Merck & Co. for ...